CB
ARQT icon

Commerce Bank’s Arcutis Biotherapeutics ARQT Stock Holding History

Commerce Bank’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$431K Buy
16,425
+3,794
+30% +$88.4K ﹤0.01% 1021
2026
Q1 		$298K Sell
12,631
-252
-2% -$6.43K ﹤0.01% 1134
2025
Q4 		$374K Sell
12,883
-3,097
-19% -$79.3K ﹤0.01% 985
2025
Q3 		$301K Sell
15,980
-875
-5% -$13.8K ﹤0.01% 1071
2025
Q2 		$236K Hold
16,855
– – ﹤0.01% 1108
2025
Q1 		$264K Sell
16,855
-230
-1% -$3.24K ﹤0.01% 1054
2024
Q4 		$238K Sell
17,085
-150
-0.9% -$1.64K ﹤0.01% 1097
2024
Q3 		$160K Sell
17,235
-535
-3% -$5.28K ﹤0.01% 1189
2024
Q2 		$165K Hold
17,770
– – ﹤0.01% 1160
2024
Q1 		$176K Buy
17,770
+140
+0.8% +$1.04K ﹤0.01% 1155
2023
Q4 		$56.9K Sell
17,630
-850
-5% -$2.31K ﹤0.01% 1170
2023
Q3 		$98.1K Sell
18,480
-525
-3% -$4.46K ﹤0.01% 1117
2023
Q2 		$181K Buy
19,005
+2,340
+14% +$26K ﹤0.01% 1106
2023
Q1 		$183K Buy
16,665
+4,000
+32% +$57.9K ﹤0.01% 1111
2022
Q4 		$187K Buy
+12,665
New +$221K ﹤0.01% 1081

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Commerce Bank's ARQT Position: Q2 2026 in Review

Commerce Bank increased its Arcutis Biotherapeutics (ARQT) stake by 30% in Q2 2026, buying an estimated $88.4K and bringing the position to 16,425 shares worth $431K. The position accounts for ﹤0.01% of the portfolio, ranked #1021.

Commerce Bank first reported a position in ARQT in Q4 2022 and has held it in 15 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Commerce Bank held 16,425 shares of Arcutis Biotherapeutics worth $431K as of Q2 2026.
  • Commerce Bank bought 3,794 Arcutis Biotherapeutics shares in Q2 2026, an estimated $88.4K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Commerce Bank's portfolio in Q2 2026, its #1021 holding.
  • Commerce Bank first reported a position in Arcutis Biotherapeutics in Q4 2022 and has held it in 15 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Commerce Bank's 13F filing for Q2 2026, filed 12 Aug 2026.